<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345213</url>
  </required_header>
  <id_info>
    <org_study_id>E2020-J081-419</org_study_id>
    <nct_id>NCT02345213</nct_id>
  </id_info>
  <brief_title>A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)</brief_title>
  <official_title>A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the efficacy of Aricept in patients with dementia
      with Lewy bodies (DLB).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician's Interview-Based Impression of Change, Plus Caregiver Input Version (CIBIC-plus)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>CIBIC plus is a clinician's interview-based impression of change plus the caregiver's input. It is a seven-point categorical assessment scale for evaluating global clinical function, ranging from &quot;markedly improved&quot; to &quot;markedly worse&quot;.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Dementia, Lewy Body</condition>
  <condition>Lewy Body Disease</condition>
  <arm_group>
    <arm_group_label>E2020</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, Weeks 7-12 E2020 10 mg.
Extension period: Weeks 1-6 E2020 10 mg, After Week 7 up to week 60 E2020 10 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment period: Weeks 1-12 placebo
Extension period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, After Week 7 up to week 60 E2020 10 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2020</intervention_name>
    <description>E2020 tablets will be orally administered once daily after breakfast</description>
    <arm_group_label>E2020</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets will be orally administered once daily after breakfast</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Patients diagnosed with probable DLB according to the diagnostic criteria for DLB

          2. Patients having caregivers throughout the study who submit written consent to
             cooperate with this study, can routinely stay with patients at least 3 days a week (at
             least 4 hours a day), provide patients' information necessary for this study, assist
             treatment compliance, and escort the patients on required visits to study institution

          3. Clinical Dementia Rating (CDR) score is greater than or equal to 0.5

          4. Mini-Mental State Examination (MMSE) score is greater than or equal to 10 and less
             than or equal to 26

        Exclusion Criteria

          1. Patients diagnosed with Parkinson's disease with dementia (PDD)

          2. Patients who have received anti-dementia drug therapy within 12 weeks before the start
             of the observation period

          3. Patients with a complication of serious neuropsychiatric disease(s) such as stroke,
             brain tumor, schizophrenia, epilepsy, normal pressure hydrocephalus, mental
             retardation, brain trauma with unconsciousness, or a history of brain surgery causing
             unrecovered deficiency

          4. Patients with severe extrapyramidal disorders (Hoehn and Yahr staging score is greater
             than or equal to IV)

          5. Patients whose systolic blood pressure is less than 90 mmHg or pulse rate is less than
             50 beats/minute at screening test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Megumi Ohdake</last_name>
    <role>Study Director</role>
    <affiliation>Drug Fostering and Evolution Coordination Department, Eisai Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2015</study_first_submitted>
  <study_first_submitted_qc>January 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLB</keyword>
  <keyword>Dementia with Lewy bodies</keyword>
  <keyword>Lewy Body Disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>E2020</keyword>
  <keyword>Donepezil</keyword>
  <keyword>Aricept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

